Work

Response to and Survival after First-Line FOLFIRINOX or Gemcitabine/Nab-Paclitaxel for Localized Pancreatic Ductal Adenocarcinoma

Year: 2021

Type: article

Source: HPB

DOI: 10.1016/j.hpb.2020.11.027

Authors: G. Perri, L. Prakash, G.R. Varadhachary, E.J. Koay, M. Kim, N. Ikoma, C. Tzeng, J.E. Lee, M.H. Katz

Institutions: University of Verona, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3143800975

FWCI:

Cites:

Cited by:

Related to: 10